NCT06061159View on ClinicalTrials.gov

The ED95 of Single Intravenous Bolus Remimazolam Besylate in Pediatric Patients During General Anesthesia Induction

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 6, 2023

Primary Completion Date

February 27, 2024

Study Completion Date

February 27, 2024

Conditions
PediatricED95SedationGeneral Anesthesia
Interventions
DRUG

Remimazolam besylate

initial dose is 0.2mg/kg；adjust dosage is 0.05mg/kg

DRUG

Remimazolam besylate

initial dose is based on the findings from the school-age group；adjust dosage is 0.05mg/kg

Trial Locations (1)

Unknown

The second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou

All Listed Sponsors
lead

Second Affiliated Hospital of Wenzhou Medical University

OTHER

NCT06061159 - The ED95 of Single Intravenous Bolus Remimazolam Besylate in Pediatric Patients During General Anesthesia Induction | Biotech Hunter | Biotech Hunter